Novel stem cell study typical of investigator-led research in PD

8 August 2018

Industry analyst GlobalData has drawn attention to a pioneering stem cell trial for Parkinson’s disease underway at Kyoto University Hospital in Japan.

The trial, which is being conducted in partnership with the Center for iPS Cell Research and Application (CiRA), is evaluating the transplantation of ‘dopaminergic progenitors’ which have been created using pluripotent stem cells.

While currently available treatment options for Parkinson’s are limited to those providing symptomatic relief of motor symptoms, the use of preprogrammed stem cells could provide a new therapeutic approach.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK